Hemispherx announces start of Merck-supported ovarian cancer clinical drug trial
Last month, tests started for combination therapy targeting metastatic, triple-negative breast cancer
Company
Merck & Co Inc
NYSE:MRK
Merck & Co Inc is a global healthcare company. The company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products.
138 stories · page 4 of 7
CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial
Leronlimab shows promise as an antiviral agent with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Investments and investor services
MIDDAY MOVERS: Twitter pounded after being called the Harvey Weinstein of social media by Andrew Left
Billionaire icon Carl Icahn raises stake in Newell Brands Inc
Moderna is biggest biotech IPO, draws $604 million despite turbulent market
The Cambridge biotech, which is developing novel messenger RNA technology, priced at the midpoint of expected range in a sign of resiliency but shares declined in their first few minutes of trading
Biotech companies dominate at Dawson James Securities Small Cap Growth Conference
Interpace Diagnostics, Hemispherx Biopharma among the standouts presenting at the investor-focused event
IPO Roundup: Urovant Sciences, EdtechX and Remora Royalty to tap the capital markets, while Volvo Cars drops IPO
All eyes are on hedge-funder-turned-biotech whiz kid Vivek Ramaswamy who is launching his fifth biotech company Urovant Sciences
Hardware & electrical equipment
IPO Roundup: Search software company Elastic to raise US$100mln as competition with Amazon heats up
The California-based company’s Elasticsearch open-source software is used by customers like Uber, Walgreens, Adobe Systems, Merck and Sprint
EARLY MOVERS: Ambarella tanks in pre-market as it lowers outlook but American Outdoor Brands Corp stock fires up
Also in focus before the New York bell was Publix and Merck & Co..
Oppenheimer reiterates Outperform rating on BioLineRx after positive data from GENISIS study of BL-8040
Meanwhile, Maxim was also pleased with the study of BL-8040 as a stem cell mobilizer for bone marrow transplants moving ahead of schedule
BioLineRx's collaboration with Merck supports the potential of BL-8040 in ‘difficult to treat cancers,’ says Maxim
The BL-8084 platform continues to make progress across multiple indications and data from several studies is expected in 2018
Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda
Drug giant raised its full-year guidance to a range of US$4.22 and US$4.30 a share compared with US$4.16 to US$4.28 a share expected last quarter
Two of AstraZeneca’s key cancer drugs win speedy approvals in Japan
Lynparza and Imfinzi are likely to play an important role if AstraZeneca is to hit its target of generating annual sales of US$45bn by 2023
AstraZeneca’s Lynparza drug sails through late-stage ovarian cancer study
The drug has already been approved for later use in ovarian and breast cancer patients, but the SOLO-1 trial has sowed it could be useful as a first-line treatment
AstraZeneca and Eli Lilly halt late-stage Alzheimer’s study as drug shows no sign of working
AstraZeneca and Lilly’s lanabecestat drug can be added to the list of failed Alzheimer’s treatments; in fact, 99% of all drugs developed to treat the disease have failed clinical trials in the past ten years
AstraZeneca and Merck present data from prostate cancer trial at ASCO 2018
The data showed that the combination of Lynparza and abiraterone can help patients with a specific form of prostate cancer to live for longer without their disease getting worse
Merck milestone payment helps Aduro Biotech to beat analyst estimates with 1Q results
Oppenheimer says company's cash position 'should continue to provide operational freedom'
Merck posts better-than-expected 1Q profits due to sales of its drug Keytruda
On an adjusted basis, the pharmaceutical giant earned US$1.05 per share, which beat the consensus estimate of $0.99
Investments and investor services
Dow falls on broad pullback, but tech rally keeps Nasdaq positive
Generally speaking, it has been a good earnings season so far for US companies, but a couple of disappointing announcements have scared investors who are already a little twitchy
Procter & Gamble acquires German Merck’s consumer health unit for US$4.2bln
P&G will add Merck's vitamins and supplements to its product line
Merck shares pop as its Keytruda drug results power ahead of Bristol-Myers, Roche
The immunotherapies boost patient survival rates, studies show